Innate Pharma Stock
Innate Pharma S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- CEO
- Jonathan E. Dickinson
- Employees
- 163
- Market cap
- $158 M
- IPO
- 17/10/2019
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing…
Innate Pharma stock: price history
1D
-3.4%
1W
-11.7%
1M
-28.9%
6M
-13.9%
YTD
-18.3%
1Y
-33.2%
2Y
-31.9%
5Y
-75.6%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~87% stronger price swings than usual
Ask the agents about Innate Pharma
Analyst assessment of Innate Pharma
PRICE TARGET LOW
US$4.00
CONSENSUS
US$6.67
MEDIAN
US$7.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
4
BUY
2
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 17/09/2026
Innate Pharma stock metrics
P/E
-2.55
P/B
-3.02
EV/EBITDA
-2.61
RETURN ON EQUITY
49.1%
NET MARGIN
-630.0%
DEBT/EQUITY
-0.5
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.0%
FLOAT SHARES
70,445,159
AVG. DAILY VOLUME (30D)
50,053
Institutional holders
Comparable stocks
Frequently asked questions about Innate Pharma stock
What does Innate Pharma do?
Innate Pharma S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in France.
The CEO is Jonathan E. Dickinson, the company employs around 163 people.
The IPO was on 17/10/2019; the stock trades on NASDAQ under the ticker IPHA.
What do analysts say about Innate Pharma stock?
6 analysts rate the stock, the consensus is Buy (as of 17/09/2026).
The average price target is US$6.67, ranging from US$4.00 to US$9.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Innate Pharma report next?
Around past earnings, price swings were roughly 87% stronger than usual.
Does Innate Pharma pay a dividend?
No, Innate Pharma currently does not pay a dividend.
Which stocks are comparable to Innate Pharma?
Comparable stocks include Nanobiotix, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Innate Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Innate Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.